GlaxoSmithKline’s HIV business
GlaxoSmithKline’s (GSK) HIV business includes Epzicom/Kivexa, Triumeq, Tivicay, Selzentry, and Jucula. GlaxoSmithKline holds the majority of shares in ViiV Healthcare, a global leader in developing advanced treatments for HIV infections. Pfizer (PFE) and Shionogi are other shareholders in ViiV Healthcare.
The chart below shows the revenues of key HIV products from GlaxoSmithKline’s portfolio since 1Q17.
GSK’s HIV products reported revenues of ~1.2 billion pounds in 4Q17, for ~13.0% growth compared to 4Q16. This growth includes an ~17.0% increase in revenues at constant exchange rates.
The segment’s growth was offset by an ~4.0% decrease in revenues due to the negative impact of foreign exchange. This growth was driven by increased sales of Tivicay and Triumeq and partially offset by lower sales of Epzicom/Kivexa.
Tivicay and Triumeq
Tivicay, which is approved for the treatment of HIV-1 infections, reported revenues of ~399.0 million pounds in 4Q17, reflecting ~38.0% growth compared to 4Q16 sales. This includes ~41.0% growth in revenues at constant exchange rates, and it was offset by an ~3.0% decrease in revenues due to the negative impact of foreign exchange.
Tivicay’s US sales increased ~28.0% to ~256.0 million pounds. The sales from the European market increased ~40.0% to ~87.0 million pounds, and international sales increased 96.0% to 56.0 million pounds.
Triumeq, another HIV drug, reported revenues of ~653.0 million pounds in 4Q17, reflecting ~23.0% growth compared to its 4Q16 sales. This includes ~27.0% growth in revenues at constant exchange rates, offset by an ~4.0% decrease in revenues due to the negative impact of foreign exchange.
Triumeq’s US sales increased ~29.0% to ~427.0 million pounds. The sales from European markets increased ~35.0% to ~166.0 million pounds, and international sales increased ~42.0% to ~60.0 million pounds in 4Q17.
Other products from GSK’s HIV business includes Epzicom/Kivexa, Selzentry, Combivir and Lexiva, and Jucula. Epzicom/Kivexa reported an ~63.0% decrease in revenues to ~42.0 million pounds in 4Q17, driven by lower sales across all markets.
Selzentry reported an ~9.0% decrease in revenues to ~30.0 million pounds in 4Q17, driven by lower sales in the US and international markets and partially offset by growth in sales in the European markets.
The company’s new drug, Jucula, launched in November 2017 and reported revenues of ~5.0 million pounds in 4Q17.
Other drugs for the treatment of HIV include Merck & Co.’s (MRK) Isentress and Bristol-Myers Squibb’s (BMY) Sustiva. Mylan (MYL) launched the first generic version of Sustiva in the US markets on February 1, 2018.